Cargando…

Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease

BACKGROUND: The ability of unstandardized methods to track kidney growth in clinical trials for autosomal dominant polycystic kidney disease (ADPKD) has not been critically evaluated. METHODS: The Tolvaptan Efficacy and Safety Management of ADPKD and its Outcomes (TEMPO) 3:4 study involved baseline...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edwards, Marie E, Blais, Jaime D, Czerwiec, Frank S, Erickson, Bradley J, Torres, Vicente E, Kline, Timothy L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Familial Nephropathies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366146/ https://www.ncbi.nlm.nih.gov/pubmed/30746130 http://dx.doi.org/10.1093/ckj/sfy078

Ejemplares similares

MYH9-related disorders display heterogeneous kidney involvement and outcome
por: Tabibzadeh, Nahid, et al.
Publicado: (2018)

Prevalence of autosomal dominant polycystic kidney disease in the European Union
por: Willey, Cynthia J., et al.
Publicado: (2017)

Podocyturia: why it may have added value in rare diseases
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2018)

New insights from the application of the FAbry STabilization indEX in a large population of Fabry cases
por: Mignani, Renzo, et al.
Publicado: (2018)

Will the FAbry STabilization indEX make its way to everyday clinical practice?
por: Cairns, Tereza, et al.
Publicado: (2018)

Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes
por: Trimarchi, Hernán, et al.
Publicado: (2018)

MYH9-related disease: it does exist, may be more frequent than you think and requires specific therapy
por: Fernandez-Prado, Raul, et al.
Publicado: (2019)

A novel heterozygous mutation in the ATP6V0A4 gene encoding the V-ATPase a4 subunit in an adult patient with incomplete distal renal tubular acidosis
por: Imai, Eri, et al.
Publicado: (2016)

Familial vasculitides: granulomatosis with polyangitis and microscopic polyangitis in two brothers with differing anti-neutrophil cytoplasm antibody specificity
por: Prendecki, Maria, et al.
Publicado: (2016)

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
por: Grantham, Jared J., et al.
Publicado: (2017)

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial
por: Casteleijn, Niek F., et al.
Publicado: (2016)

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4
por: Devuyst, Olivier, et al.
Publicado: (2017)

Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys
por: Kline, Timothy L., et al.
Publicado: (2017)

Automatic semantic segmentation of kidney cysts in MR images of patients affected by autosomal-dominant polycystic kidney disease
por: Kline, Timothy L., et al.
Publicado: (2020)

Changes in metformin use in chronic kidney disease
por: Imam, Talha H.
Publicado: (2017)

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial
por: Irazabal, Maria V., et al.
Publicado: (2016)

Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
por: Perrone, Ronald D., et al.
Publicado: (2017)

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
por: Watkins, Paul B., et al.
Publicado: (2015)

Kidney volume and function in autosomal dominant polycystic kidney disease
por: Higashihara, Eiji, et al.
Publicado: (2013)

Kidney and cystic volume imaging for disease presentation and progression in the cat autosomal dominant polycystic kidney disease large animal model
por: Yu, Yoshihiko, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial
por: Shoaf, Susan E., et al.
Publicado: (2017)

Autosomal dominant polycystic kidney
por: Gudadhe, Rugaved Raghavendra, et al.
Publicado: (2022)

A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease
por: Perrone, Ronald D., et al.
Publicado: (2017)

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
por: Torres, Vicente E, et al.
Publicado: (2018)

Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease
por: Tangri, Navdeep, et al.
Publicado: (2017)

Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease
por: Martin, William P., et al.
Publicado: (2019)

Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases
por: Higashihara, Eiji, et al.
Publicado: (2018)

Clinical Quality Control of MRI Total Kidney Volume Measurements in Autosomal Dominant Polycystic Kidney Disease
por: Zhu, Chenglin, et al.
Publicado: (2023)

Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease
por: Sharma, Kanishka, et al.
Publicado: (2017)

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial
por: Cornec-Le Gall, Emilie, et al.
Publicado: (2018)

Bone health in autosomal dominant polycystic kidney disease (ADPKD) patients after kidney transplantation
por: Zubidat, Dalia, et al.
Publicado: (2023)

Automatic Segmentation of Kidneys using Deep Learning for Total Kidney Volume Quantification in Autosomal Dominant Polycystic Kidney Disease
por: Sharma, Kanishka, et al.
Publicado: (2017)

Impact of kidney function and kidney volume on intracranial aneurysms in patients with autosomal dominant polycystic kidney disease
por: Kataoka, Hiroshi, et al.
Publicado: (2022)

Autosomal dominant polycystic kidney disease in Colombia
por: Camargo, Jessica T., et al.
Publicado: (2023)

Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling
por: Zhou, Xia, et al.
Publicado: (2022)

Apelin is altered in subjects with autosomal dominant polycystic kidney disease and preserved kidney function
por: Janssens, Peter, et al.
Publicado: (2023)

Association of Vitamin D Levels With Kidney Volume in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Vendramini, Larissa Collis, et al.
Publicado: (2019)

Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies
por: Chebib, Fouad T., et al.
Publicado: (2017)

Utilizing magnetization transfer imaging to investigate tissue remodeling in a murine model of autosomal dominant polycystic kidney disease
por: Kline, Timothy L., et al.
Publicado: (2015)

Introduction of laparoscopic nephrectomy for autosomal dominant polycystic kidney disease as the standard procedure
por: Thomas, M. N., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vki7ufg13b1cutj5nfn1jv9j15